STOCK UPDATE – Reliance Industries Ltd, Hindustan Unilever Ltd, UltraTech Cement Ltd, Polycab India Ltd;
VIEWPOINT – Shoppers Stop Ltd.
FIIs net sell ₹545.58 crore & DIIs net sell ₹719.31 crore in equities today (Provisional)
Читать полностью…Atul Mehra resigns as Joint Managing Director of JM Financial w.e.f. April 20, 2024
Читать полностью…PERSISTENT SYSTEMS: CO DECLARED AN INTERIM DIVIDEND OF RUPEES 32 PER SHARE FOR FY24
Читать полностью…Markets Today | 📊Nifty closes below 21,600 mark dragged by HUL, TCS
📈Here's how markets performed today
TATVA CHINTAN PHARMA CHEM: Q3 CONS NET PROFIT 35M RUPEES VS 116M (YOY)
TATVA CHINTAN PHARMA CHEM: Q3 EBITDA 110M RUPEES VS 179M (YOY) || Q3 EBITDA MARGIN 13.06% VS 14.84% (YOY)
POOR EBITDA
POOR SHOW
SHREE DIGVIJAY CEMENT says
Guidance
🎯 Volumes +6% to 7% in FY24
🎯 EBITDA sustainable at ₹1400-1500/tn
🚨Sold stake due to personal reasons 🚨
🤔 Believe that company is still undervalued
👍 Expansion will come on from Dec 2024
200+ years old Reliable Trading Theory
• Every Investor Must Know
• Secrets of Dow theory
• How to Catch Market Trend
• Volume & Price Action
Watch Now ⤵️
https://youtu.be/xKdLB-5vNUA
Like & Share 👍
J&K Bank reports #Q3 earnings
-Net Profit up 35.1% at ₹421.1 cr vs ₹311.6 cr (YoY)
-NII up 1.8% at ₹1,280 cr vs ₹1,257.4 cr (YoY)
-Gross NPA at 4.84% vs 5.26% (QoQ)
-Net NPA at 0.83% vs 1.04% (QoQ)
-Gross NPA at 4,528.5 Cr vs
4,826.7 Cr (QoQ)
-Net NPA at 740.8 Cr vs
917.4 Cr (QoQ)
ICICI Bank Concall: These are the highlights on credit-deposit ratio, capital adequacy ratio, NIMs and other factors
Читать полностью…#KotakMahindraBank to raise Rs 10,000 crore via #NCDs in one or more tranches during FY25: Exchange Filing
Читать полностью…PersistentSystems appoints key managerial personnel to lead its global growth plans.
Читать полностью…Adani Group has received order from SECI to set up electrolyser manufacturing facility for green hydrogen under PLI.
Читать полностью…200+ years old reliable theory*
Secret of Dow theory
How to catch market trend
Volume n price action 😎
*Watch now 👇*
https://youtu.be/xKdLB-5vNUA
Like n share 👍
Tatva Chintan Pharma reports its Q3 earnings:
-Net Profit down 69.8% at ₹3.5 cr vs ₹11.6 cr (YoY)
-Revenue down 30.2% at ₹84.2 cr vs ₹120.6 cr (YoY)
-EBITDA down 38.5% at ₹11 cr vs ₹17.9 cr (YoY)
-Margin at 13.1% vs 14.8% (YoY)
Ashok Vaswani addresses KotakMahindraBank Q3FY24 Press Conference for the first time as CEO.
Читать полностью…Seshasayee Paper reports #Q3RESULTS
-Cons Net Profit down 38.4% at ₹69 Cr vs ₹112 Cr (YoY)
-Revenue down 15% at ₹473.5 cr Vs ₹556 cr (YoY)
-EBITDA down 41% at ₹88 cr vs ₹151 cr (YoY)
-Margin at 18.7% vs 27.2% (YoY)
SESHASAYEE PAPER & BOARDS: Q3 CONS NET PROFIT 690M RUPEES VS 1.11B (YOY)
SESHASAYEE PAPER & BOARDS: Q3 REVENUE 4.7B RUPEES VS 5.56B (YOY)
SESHASAYEE PAPER & BOARDS: Q3 EBITDA 885M RUPEES VS 1.5B (YOY) || Q3 EBITDA MARGIN 18.67% VS 26.96% (YOY)
POOR EBITDA AND MARGINS
POOR SHOW